Physician profile
Hamant B Patel
NPI 1962459222
$5,702.01
in general payments reported to CMS, 2019-2025
36 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $401 · 2021: $738 · 2022: $996 · 2023: $858 · 2024: $634 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,329.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $618.60 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $524.62 | 2021-2025 | |
| Amgen INC. | $502.85 | 2019-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $390.82 | 2023-2025 | Caplyta |
| Astellas Pharma US INC | $308.68 | 2019-2025 | Veozah |
| Allergan, INC. | $250.04 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.98 | 2022-2025 | |
| Pfizer INC. | $150.95 | 2020-2025 | |
| Abbott Laboratories | $147.66 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $122.04 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $121.08 | 2019-2022 | |
| Beta Bionics, INC. | $119.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Avanir Pharmaceuticals, INC. | $88.95 | 2021-2022 | |
| Lilly USA, LLC | $74.74 | 2023-2025 | Mounjaro, Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $73.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.34 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $59.41 | 2020-2025 | Spravato |
| Mannkind Corporation | $59.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $50.46 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $47.59 | 2023-2025 | Rexulti, Nuedexta |
| Abiomed | $45.46 | 2023 | Impella |
| Teva Pharmaceuticals USA, INC. | $39.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.64 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $28.60 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $24.53 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.54 | 2022 | |
| Redhill Biopharma INC. | $22.30 | 2021 | |
| Inspire Medical Systems, INC. | $21.59 | 2025 | Inspire |
| Tolmar, INC. | $18.00 | 2023 | |
| Aytu Biopharma, INC. | $17.33 | 2019 | |
| Medtronic, INC. | $15.94 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.60 | 2025 | Nuzyra |
| Athena Bioscience, LLC | $14.97 | 2025 | Nexiclon Xr |
| Dexcom, INC. | $14.84 | 2021 | |
| Eisai INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.